argenex (NASDAQ:ARGX) Price Target Raised to $1,230.00

argenex (NASDAQ:ARGX) had its price target boosted by Morgan Stanley from $1,200.00 to $1,230.00 in a research report released on Tuesday,Benzinga reports. Morgan Stanley currently has an overweight rating on the stock.

A number of other equities analysts have also weighed in on ARGX. Citigroup lifted their price objective on shares of argenex from $1,152.00 to $1,182.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. HC Wainwright upped their price objective on shares of argenex from $940.00 to $1,202.00 and gave the stock a “buy” rating in a research report on Tuesday. Weiss Ratings cut shares of argenex from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, July 23rd. Wedbush lifted their target price on shares of argenex from $1,050.00 to $1,150.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, Citizens Jmp boosted their price target on shares of argenex from $932.00 to $1,200.00 and gave the stock a “market outperform” rating in a research note on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, argenex has an average rating of “Moderate Buy” and an average target price of $1,118.28.

argenex Trading Up 0.5%

Shares of ARGX stock opened at $1,038.12 on Tuesday. The company has a market capitalization of $64.94 billion, a P/E ratio of 39.87, a price-to-earnings-growth ratio of 1.09 and a beta of 0.46. The business’s 50 day moving average is $892.22 and its two-hundred day moving average is $825.72. argenex has a twelve month low of $658.60 and a twelve month high of $1,039.30.

argenex (NASDAQ:ARGX) last released its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, topping the consensus estimate of $5.86 by $1.46. argenex had a return on equity of 43.59% and a net margin of 32.19%.The business had revenue of $1.54 billion during the quarter, compared to analysts’ expectations of $1.45 billion. As a group, equities analysts predict that argenex will post 28.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ARGX. Janus Henderson Group PLC raised its position in argenex by 3.4% in the first quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock worth $1,847,592,000 after acquiring an additional 83,568 shares in the last quarter. M&T Bank Corp lifted its holdings in argenex by 20,977.7% in the fourth quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock valued at $654,772,000 after acquiring an additional 774,916 shares during the period. Wellington Management Group LLP boosted its position in shares of argenex by 80.1% during the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after purchasing an additional 324,653 shares in the last quarter. Morgan Stanley boosted its position in shares of argenex by 19.2% during the 4th quarter. Morgan Stanley now owns 518,852 shares of the company’s stock worth $436,331,000 after purchasing an additional 83,746 shares in the last quarter. Finally, Invesco Ltd. grew its stake in shares of argenex by 390.4% during the 4th quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock worth $350,178,000 after purchasing an additional 331,489 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

Key Headlines Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: HC Wainwright raised its price target to $1,202 and lifted long-term earnings forecasts. The firm increased its FY2027 EPS estimate to $34.82 from $34.38, FY2028 to $44.72 from $43.50, FY2029 to $56.38 from $53.47, and FY2030 to $76.63 from $64.39. HC Wainwright maintained its “Buy” rating, signaling confidence in argenx’s long-term growth. HC Wainwright Boosts argenx Price Target
• Positive Sentiment: Other analysts also increased their targets. Morgan Stanley raised its target to $1,230, Wedbush lifted its target to $1,150, and Citi reiterated a “Buy” rating. Citizens JMP and Piper Sandler also forecast substantial appreciation potential, reinforcing the positive analyst sentiment. Wedbush Raises argenx Price Target Morgan Stanley Raises argenx Price Target argenx Receives a Buy from Citi
• Positive Sentiment: Oppenheimer said recent myositis data helps derisk the opportunity for Vyvgart. The assessment supports investor expectations that argenx may expand Vyvgart’s commercial reach and sustain revenue growth. argenx Myositis Data Derisk Vyvgart Opportunity
• Neutral Sentiment: The stock’s valuation is elevated, with a price-to-earnings ratio near 40, so continued gains depend on argenx converting its clinical pipeline and Vyvgart opportunity into the strong earnings growth analysts now project.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.